GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » Retained Earnings

Akums Drugs and Pharmaceuticals (BOM:544222) Retained Earnings : ₹0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Akums Drugs and Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2024 was ₹0 Mil.

Akums Drugs and Pharmaceuticals's quarterly retained earnings declined from Mar. 2024 (₹6,308 Mil) to Sep. 2024 (₹0 Mil) but then stayed the same from Sep. 2024 (₹0 Mil) to Dec. 2024 (₹0 Mil).

Akums Drugs and Pharmaceuticals's annual retained earnings increased from Mar. 2022 (₹5,576 Mil) to Mar. 2023 (₹6,385 Mil) but then declined from Mar. 2023 (₹6,385 Mil) to Mar. 2024 (₹6,308 Mil).


Akums Drugs and Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Retained Earnings Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Retained Earnings
8,323.81 5,576.29 6,385.36 6,308.45

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial 4,817.32 - 6,308.45 - -

Akums Drugs and Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Akums Drugs and Pharmaceuticals  (BOM:544222) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Akums Drugs and Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines